Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Jie Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9568-2432; OpenAlex author ID A5100454162. Sources: OpenAlex.

Their work

Papers
8 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
17
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 4 papers · 2025: 1 paper

Papers 8

  1. Tumor-derived exosomal CCT6A serves as a matchmaker introducing chemokines to tumor-associated macrophages in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-025-07720-y↗
  2. Correction: Phosphoglycerate dehydrogenase promotes pancreatic cancer development by interacting with eIF4A1 and eIF4E. Co-author DOI 10.1186/s13046-024-03252-z↗
  3. Illuminating the immunological landscape: mitochondrial gene defects in pancreatic cancer through a multiomics lens. Co-author DOI 10.3389/fimmu.2024.1375143↗
  4. A single-cell perspective on immunotherapy for pancreatic cancer: from microenvironment analysis to therapeutic strategy innovation. First author DOI 10.3389/fimmu.2024.1454833↗
  5. Deciphering the role of NcRNAs in Pancreatic Cancer immune evasion and drug resistance: a new perspective for targeted therapy. Co-author DOI 10.3389/fimmu.2024.1480572↗
  6. Phosphoglycerate dehydrogenase promotes pancreatic cancer development by interacting with eIF4A1 and eIF4E. Co-author DOI 10.1186/s13046-019-1053-y↗
  7. Value of magnetic resonance images in preoperative staging and resectability assessment of pancreatic cancer. First author DOI 10.4103/jcrt.jcrt_590_17↗
  8. URG11 predicts poor prognosis of pancreatic cancer by enhancing epithelial-mesenchymal transition-driven invasion. Last author DOI 10.1007/s12032-014-0064-y↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yongzhang Luo · 2 shared papers, 2019–2024 · strength 0.40
  2. Xuhui Ma · 2 shared papers, 2019–2024 · strength 0.40
  3. Bo Li · 2 shared papers, 2024 · strength 0.38
  4. Xiaoli Yang · 2 shared papers, 2024 · strength 0.38
  5. Tianyin Ma · 1 shared paper, 2025 · strength 0.21
  6. Peng Xia · 1 shared paper, 2025 · strength 0.21
  7. Chengming Qu · 1 shared paper, 2025 · strength 0.21
  8. Ming Tian · 1 shared paper, 2025 · strength 0.21
  9. Yufeng Yuan · 1 shared paper, 2025 · strength 0.21
  10. Hao Chi · 1 shared paper, 2024 · strength 0.20
  11. Guanhu Yang · 1 shared paper, 2024 · strength 0.20
  12. Yu Gong · 1 shared paper, 2024 · strength 0.19
  13. Lai Jiang · 1 shared paper, 2024 · strength 0.19
  14. Rui Wang · 1 shared paper, 2024 · strength 0.19
  15. Changfu Wang · 1 shared paper, 2018 · strength 0.10
  16. Shufang Yang · 1 shared paper, 2018 · strength 0.10
  17. Wei Jun Peng · 1 shared paper, 2014 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.